Samsung Biologics Co.,Ltd. (207940.KS)
KRW 959000.0
(-2.14%)
KRW 959000.0
(-2.14%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1541.39 Billion KRW | -5.04% |
| 2022 | 1623.21 Billion KRW | 30.34% |
| 2021 | 1245.33 Billion KRW | 64.72% |
| 2020 | 756.05 Billion KRW | 43.03% |
| 2019 | 528.6 Billion KRW | -38.18% |
| 2018 | 855.07 Billion KRW | 355.25% |
| 2017 | 187.82 Billion KRW | -69.35% |
| 2016 | 612.71 Billion KRW | -6.8% |
| 2015 | 657.39 Billion KRW | 73.25% |
| 2014 | 379.43 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 708.01 Billion KRW | 8.98% |
| 2024 Q1 | 649.69 Billion KRW | -57.85% |
| 2023 Q2 | 1833.96 Billion KRW | 98.0% |
| 2023 Q3 | 1916.45 Billion KRW | 4.5% |
| 2023 Q4 | 1541.39 Billion KRW | -19.57% |
| 2023 FY | 1541.39 Billion KRW | -5.04% |
| 2023 Q1 | 926.22 Billion KRW | -42.94% |
| 2022 FY | 1623.21 Billion KRW | 30.34% |
| 2022 Q4 | 1623.21 Billion KRW | -22.88% |
| 2022 Q3 | 2104.76 Billion KRW | 4.13% |
| 2022 Q1 | 911.29 Billion KRW | -26.82% |
| 2022 Q2 | 2021.24 Billion KRW | 121.8% |
| 2021 Q2 | 515.96 Billion KRW | -25.03% |
| 2021 Q4 | 1245.33 Billion KRW | 17.99% |
| 2021 Q1 | 688.23 Billion KRW | -8.97% |
| 2021 FY | 1245.33 Billion KRW | 64.72% |
| 2021 Q3 | 1055.46 Billion KRW | 104.56% |
| 2020 Q1 | 567.73 Billion KRW | 7.4% |
| 2020 Q2 | 522.11 Billion KRW | -8.03% |
| 2020 Q3 | 552.98 Billion KRW | 5.91% |
| 2020 FY | 756.05 Billion KRW | 43.03% |
| 2020 Q4 | 756.05 Billion KRW | 36.72% |
| 2019 Q4 | 528.6 Billion KRW | -23.92% |
| 2019 FY | 528.6 Billion KRW | -38.18% |
| 2019 Q3 | 694.76 Billion KRW | -14.3% |
| 2019 Q2 | 810.7 Billion KRW | -0.69% |
| 2019 Q1 | 816.36 Billion KRW | -4.53% |
| 2018 FY | 855.07 Billion KRW | 355.25% |
| 2018 Q1 | 328.55 Billion KRW | 74.93% |
| 2018 Q2 | 803.7 Billion KRW | 144.62% |
| 2018 Q3 | 865.71 Billion KRW | 7.72% |
| 2018 Q4 | 855.07 Billion KRW | -1.23% |
| 2017 Q2 | 56.46 Billion KRW | -85.38% |
| 2017 Q1 | 386.35 Billion KRW | -36.94% |
| 2017 FY | 187.82 Billion KRW | -69.35% |
| 2017 Q3 | 181.71 Billion KRW | 221.8% |
| 2017 Q4 | 187.82 Billion KRW | 3.36% |
| 2016 FY | 612.71 Billion KRW | -6.8% |
| 2016 Q4 | 612.71 Billion KRW | 0.0% |
| 2015 FY | 657.39 Billion KRW | 73.25% |
| 2014 FY | 379.43 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | -3.06 Billion KRW | 50320.842% |
| Green Cross Holdings Corporation | 1105.62 Billion KRW | -39.413% |
| Green Cross Holdings Corporation | 674.31 Billion KRW | -128.587% |
| Pharmicell Co., Ltd. | -10.69 Billion KRW | 14510.478% |
| Green Cross Corporation | 674.31 Billion KRW | -128.587% |
| GeneOne Life Science, Inc. | 8.04 Billion KRW | -19050.698% |
| Celltrion, Inc. | 1325.8 Billion KRW | -16.261% |
| SK bioscience Co.,Ltd. | -106.45 Billion KRW | 1547.971% |
| SK Biopharmaceuticals Co., Ltd. | -61.64 Billion KRW | 2600.236% |
| Prestige BioPharma Limited | -129.76 Billion KRW | 1287.826% |